Oct. 31, 2019:
Applications are now open for a nationwide integrative oncology training program. The Integrative Oncology Scholars Program at the University of Michigan is funded by a National Cancer Institute R25 grant. It has the joint goals of training 100 integrative oncology (IO) leaders over 4 years and facilitating partnerships between IO leaders and complementary practitioners within their communities. Read More
Oct. 10, 2019: Investigators from Big Ten Cancer Research Consortium (Big Ten CRC) member institutions gathered at Big Ten Conference Headquarters in Chicago for the consortium’s annual summit, September 21. The 2019 Summit, hosted by the University of Iowa Holden Comprehensive Cancer Center, featured topics presented by Big Ten investigators and industry representatives, and opportunities to discuss current and potential collaborations. Read More
Oct. 1, 2019: In this month’s Across the Consortium, the Big Ten Cancer Research Consortium (Big Ten CRC) welcomes members to new leadership roles. We also highlight some of the work universities are doing to support cancer survivors and increase their quality of life after cancer, while researchers continue to explore novel approaches to improve survival and prevent relapses. Read More
Sept. 25, 2019: In this month’s Across the Consortium, the Big Ten Cancer Research Consortium (Big Ten CRC) highlights a wide range of topics from newly activated Big Ten CRC studies, research with cancer and genomics, rare cancers, and developing new strategies to integrate patient education in regular cancer care visits. Read More
Sept. 18, 2019: Muhammad Furqan, MD, a medical oncologist and clinical associate professor of internal medicine – Hematology, Oncology and Blood and Marrow Transplantation at the University of Iowa Carver College of Medicine, will represent the university on the Big Ten Cancer Research Consortium (Big Ten CRC) Steering Committee. As a collaboration of Big Ten universities, the Big Ten CRC leverages the scientific and clinical expertise of its members by developing and conducting early-phase oncology clinical trials that can provide access to novel treatments to patients with cancer. Dr. Furqan specializes in lung cancer and leads the thoracic multidisciplinary oncology group at the Read More
Sept. 16, 2019: Every year, selected junior investigators learn how to design effective clinical trials for therapeutic interventions in treating cancer during an intensive week-long workshop hosted jointly by the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR). The conference, known in oncology circles as the “Vail Workshop,” is held in Vail, Colo. and is an ideal backdrop for clinical and research oncologists to unplug, network, and gain valuable feedback from leading investigators in oncology in a retreat-like setting. “For junior investigators, the Read More
Sept. 3, 2019: The Ohio State University has appointed Peter Shields, MD, to serve as the university's representative on the Big Ten Cancer Research Consortium (Big Ten CRC) Steering Committee. Dr. Shields, a thoracic medical oncologist and deputy director of The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James), oversees the scientific research programs and research infrastructure of the OSUCCC-James, which includes more than 340 cancer researchers and their teams from 11 of Ohio State’s 15 colleges. His research focus and...
Aug. 19, 2019: The Big Ten Cancer Research Consortium recently appointed 11 investigators to serve as Big Ten CRC Clinical Trial Working Group (CTWG) co-chairs in their respective specialties. Their leadership supports the valuable collaboration and mentorship that takes place within each working group in support of Big Ten CRC studies, through initial review and approval of study concepts, protocol review, feedback throughout the life of a study, and publication authorship. It is also a forum where investigators can engage and share research concepts and flesh out ideas to shape protocols for future clinical trials. Typically, co-chairs serve two-year terms that are renewable for one more term. They are responsible for identifying topics, developing agendas, and facilitating meetings and teleconferences for their working...
Aug. 16, 2019: A new Big Ten Cancer Research Consortium study will test the efficacy and safety of combining abemaciclib and pembrolizumab in patients with unresectable or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, who are still fighting their cancers after prior treatment. The single arm, phase II study will be led by the University of Wisconsin Carbone Cancer Center in Madison, Wis. Current treatment for patients with unresectable or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma involves chemotherapy in earlier lines, but despite aggressive treatments, survival remains poor. New combination strategies are being tested to determine whether patient outcomes can improve.
Aug. 16, 2019: A clinical trial conducted by the Big Ten Cancer Research Consortium (Big Ten CRC) geared to adult patients with advanced Stage IV non-squamous non-small lung cancer will test how participants respond to a combined treatment therapy and how long the cancer can be controlled before it returns. The Big Ten CRC will also check toxicity levels in tissue and blood markers. The multicenter, single-arm, phase II clinical trial, BTCRC-LUN17-139, led by Nasser H. Hanna, MD, at Indiana University Melvin and Bren Simon Cancer Center, will build on the foundation of chemotherapy and immunotherapy, and add antiangiogenic therapy, which is intended to block the...
University of Illinois
Indiana University
University of Iowa
University of Maryland
University of Michigan
Michigan State
University of Minnesota
University of Nebraska
Northwestern University
Penn State University
Purdue University
Rutgers State University
University of Wisconsin
University of Illinois at Chicago
© 2024 All rights reserved.
Big Ten Cancer Research Consortium
7676 Interactive Way, Suite 120, Indianapolis, IN 46278
Subscribe to the Big Ten CRC Newsletter
X
Facebook
YouTube